Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
31.03.2023 |
|
31.12.2022 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
759 |
|
1 948 |
|
Securities |
|
3 |
|
2 594 360 |
|
3 051 349 |
|
Other assets |
|
|
|
214 |
|
92 |
|
|
|
|
|
2 595 333 |
|
3 053 389 |
|
Total assets |
|
|
|
2 595 333 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
4 |
|
315 500 |
|
363 000 |
|
Other short-term liabilities |
|
|
|
3 770 |
|
4 143 |
|
Tax liabilities |
|
|
|
94 |
|
111 |
|
|
|
|
|
319 364 |
|
367 254 |
|
Total liabilities |
|
|
|
319 364 |
|
367 254 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
5 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
5 |
|
(36 508) |
|
(36 508) |
|
Retained earnings |
|
|
|
2 301 397 |
|
2 711 563 |
|
|
|
|
|
2 275 969 |
|
2 686 135 |
|
Total liabilities and shareholders' equity |
|
|
|
2 595 333 |
|
3 053 389 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
41.50 |
|
49.00 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on April 18, 2023.